August 13, 2024Today, the Centers for Medicare and Medicaid Services (CMS) released the Maximum Fair Prices (MFPs) for 10 selected medicines to go into effect in 2026. PILMA reiterates our opposition to MFPs, which are simply government price controls on medicines in Medicare under the guise of negotiation. PILMA has

July 23, 2024 The labor and industry partners of the Pharmaceutical Industry Labor- Management Association (PILMA) applaud the House Oversight Committee’s investigation into the role of PBMs in prescription drug markets. PILMA has a long history of supporting increased transparency and accountability in the prescription drug supply chain and has

By Rebecca Robbins and Reed Abelson This is the first article in a series about how pharmacy benefit managers prioritize their interests, often at the expense of patients, employers and taxpayers. Americans are paying too much for prescription drugs. It is a common, longstanding complaint. And the culprits seem obvious: Drug companies. Insurers.

Thank you, Chair Durbin, Ranking Member Graham, and members of the Senate Judiciary Committee, for holding this important hearing today. We appreciate the Committee’s leadership in exploring opportunities to ensure affordable and accessible medications. We share the perspective raised by several witnesses that a healthy prescription drug market rests on